Relmada Therapeutics

About:

Relmada Therapeutics is a biotech company addressing diseases of the central nervous system, with a focus on major depressive disorder.

Website: http://www.relmada.com

Twitter/X: relmada

Top Investors: BioAdvance, Ben Franklin Technology Partners of Southeastern Pennsylvania

Description:

Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Our experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 has entered late-stage development as an adjunctive treatment for MDD in adults.()